National academy

Empress Announces Formation of World Leading Scientific Advisory Board

Retrieved on: 
Tuesday, January 23, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, Probability, Microbiome, Emperor, Harvard Medical School, National academy, Computational biology, Genetic engineering, Inflammatory bowel disease, University, Infection, Biological engineering, Therapy, Synthetic biology, DNA, Harvard University, Biostatistics, Biomedical engineering, MIT, Disease, NIH, Science Publishing Group, MacArthur Fellows Program, Metabolism, Wyss Institute, Entrepreneurship, Artificial intelligence, Cell growth, Distinguishing, Immunology, SAB, Dysbiosis, Microbiota, Biology, Dana–Farber Cancer Institute, Huntsman Cancer Institute, Mass spectrometry, Princeton University, Genomics, Public health, Protein, Diabetes, Pharmaceutical industry

Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.

Key Points: 
  • Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.
  • The SAB will work closely with the leadership at Empress Therapeutics to advance the company’s Chemilogics™ platform and pipeline of drug leads.
  • “We are honored to have these extraordinary scientific leaders join Empress in its mission to generate safe, effective medicines faster and more predictably,” said Jason Park, Ph.D., Co-Founder and CEO of Empress Therapeutics.
  • “Our Scientific Advisory Board provides invaluable expertise across multiple aspects of our Chemilogics™ platform, which uses AI to discover therapeutic chemistry encoded in genetic data.

IonQ Co-Founder Dr. Jungsang Kim Elected Fellow of the National Academy of Inventors

Retrieved on: 
Wednesday, January 17, 2024
Defense, Military, Automotive Manufacturing, Logistics, Supply Chain Management, Air, Manufacturing, Transport, Other Technology, Other Energy, Other Science, Utilities, Software, Research, Networks, Other Defense, Internet, Contracts, Alternative Energy, Hardware, Energy, Automotive, Technology, Semiconductor, Science, Nanotechnology, General Automotive, Government Technology, NAI, University, Invention, Multimedia, Partnership, Barium, National academy, Government, Patent, Television

IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced co-founder Dr. Jungsang Kim has been named a 2023 fellow of the National Academy of Inventors (NAI), the highest professional distinction awarded solely to inventors.

Key Points: 
  • IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced co-founder Dr. Jungsang Kim has been named a 2023 fellow of the National Academy of Inventors (NAI), the highest professional distinction awarded solely to inventors.
  • Kim joins an esteemed cohort of NAI fellows who will be honored during the NAI’s 13th annual conference on June 16-18 in Raleigh, NC.
  • Throughout his career, Kim has accumulated 35 patents, 19 of which are licensed to IonQ.
  • To learn more about how you can get started on an IonQ system today, please visit https://ionq.com/get-ready

Nursing Community Coalition Urges Congress to Protect Veterans' Access to Quality Anesthesia Care

Retrieved on: 
Friday, January 26, 2024
Student, Patient, Navy, Legislation, NCC, RNS, Health, Anesthesia, Multimedia, National academy, Faculty, Nursing, FAAN, Air force, Doctor of Philosophy, Letter, Registered nurse, Organization, DNP, Education, Army

The proposed legislation would impose unnecessary and unjustifiable restrictions on Certified Registered Nurse Anesthetists (CRNAs) within the Department of Veterans Affairs (VA), adversely impacting the healthcare of our nation's veterans.

Key Points: 
  • The proposed legislation would impose unnecessary and unjustifiable restrictions on Certified Registered Nurse Anesthetists (CRNAs) within the Department of Veterans Affairs (VA), adversely impacting the healthcare of our nation's veterans.
  • The NCC points out that even the VA, in testimony before the House Veterans Affairs Health Subcommittee on September 19, 2023, acknowledged that CRNAs can safely provide anesthesia care autonomously.
  • The NCC represents a diverse cross-section of the nursing profession, including Registered Nurses (RNs), APRNs, nurse leaders, boards of nursing, students, faculty, and researchers.
  • "CRNAs play a crucial role in providing anesthesia services across the entire care continuum, bringing essential support and expertise to their patients, especially within the VA," said AANA President Dru Riddle, PhD, DNP, CRNA, FAAN .

Atlanta University Center (AUC) Library CEO & Director, Loretta Parham to Retire This Year

Retrieved on: 
Thursday, January 25, 2024
Knowledge, Carnegie library, Student, Research, Spelman College, ALA, African Americans, Manuscript, OCLC, Interdenominationalism, Female, Faculty, Clark Atlanta University, History, Initiative, Trustee, Strategic planning, AUC, Morehouse College, ACRL, SOLINET, National academy, Retirement, Archive, Chicago Public Library, Library, Book

ATLANTA, Jan. 25, 2024 /PRNewswire/ -- Loretta Parham, chief executive officer and director of the Robert W. Woodruff Library of the Atlanta University Center Inc., will retire after 19 years of outstanding leadership of the Library.

Key Points: 
  • ATLANTA, Jan. 25, 2024 /PRNewswire/ -- Loretta Parham, chief executive officer and director of the Robert W. Woodruff Library of the Atlanta University Center Inc., will retire after 19 years of outstanding leadership of the Library.
  • The Board of Trustees and governing body of the AUC Woodruff Library is announcing her planned retirement date of June 2024.
  • Parham received her master's degree from the University of Michigan and her bachelor's degree from Southern Illinois University.
  • The Library's Board of Trustees will launch a national executive search for the next AUC Woodruff Library CEO and Director.

A #1 Rated Diet App Announces Addition of Professional Connect Service for Dietitians and Trainers to Work with Their Clients

Retrieved on: 
Tuesday, January 23, 2024
App Store (iOS/iPadOS), Connect, Sleep, Diet, Google Play, Medicine, Water, National academy, Exercise

BOCA RATON, Fla., Jan. 23, 2024 /PRNewswire-PRWeb/ -- MyNetDiary recently announced the addition of free Professional Connect service to its popular mobile diet and weight-loss apps, as well as its online service at mynetdiary.com. Professional Connect now enables trusted, invitation-only connections between nutrition and fitness professionals and their clients. According to MyNetDiary CEO and founder Sergey Oreshko, a dietitian or a fitness trainer, for example, can review client nutrition, exercise, and anything else the client tracks in MyNetDiary. "They can provide valuable feedback through built-in messaging with clients," says Oreshko.

Key Points: 
  • MyNetDiary, a top-rated diet app, has launched a free Professional Connect service to empower health professionals to work effectively with their clients.
  • BOCA RATON, Fla., Jan. 23, 2024 /PRNewswire-PRWeb/ -- MyNetDiary recently announced the addition of free Professional Connect service to its popular mobile diet and weight-loss apps, as well as its online service at mynetdiary.com.
  • Professional Connect now enables trusted, invitation-only connections between nutrition and fitness professionals and their clients.
  • "MyNetDiary is a top-rated mobile app on the App Store and Google Play and has became the #1 diet app for professionals to recommend to their clients.

CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL

Retrieved on: 
Monday, January 22, 2024
COVAXIN, World Health Organization, Texas Children's Hospital, UNICEF, COVID19, Tropical medicine, Dean (education), EUL, Medicine, DRS, CVD, BCM, National academy, Baylor College of Medicine, UN, RBD, Baylor University, GMP, Good, CDSCO, Dean, WHO, Safety, COVID-19, Hospital, Biomedical Research, Good manufacturing practice, Nobel Peace Prize, Alum, Vaccine, DCGI, SARS-CoV-2, National school, Biology

HOUSTON, Jan. 22, 2024 /PRNewswire/ -- Texas Children's Hospital announces today that Biological E's CORBEVAX®, a traditional, recombinant protein-based COVID-19 vaccine has received World Health Organization (WHO) approval under Emergency Use Listing (EUL). CORBEVAX® is developed and commercialized by Biological E Limited, an established global vaccine supplier based in Hyderabad, India, using Pichia pastoris yeast strain expressing Receptor Binding Domain (RBD) protein of SARS-CoV-2 engineered by Texas Children's Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine (BCM),

Key Points: 
  • "The recombinant yeast strains enable production of the RBD protein which can be further utilized by vaccine researchers globally to develop & manufacture effective and low-cost vaccines.
  • By providing access to the yeast strains via non-exclusive licensing, we continue our mission to support global vaccine accessibility and availability."
  • Biological E subsequently developed large scale manufacturing technology for production of the RBD protein complying with Good Manufacturing Practices (GMP) as well as testing & characterization suitable for use as vaccine antigen.
  • The RBD protein was then used as an antigen and formulated with optimized adjuvants (Alum and CpG1018) to develop a COVID-19 candidate vaccine.

MARCH OF DIMES AWARDS MARISA BARTOLOMEI, PHD, THE 2024 MARCH OF DIMES RICHARD B. JOHNSTON, JR., MD PRIZE

Retrieved on: 
Thursday, January 18, 2024
Assistant professor, Pediatrics, Research, Mentorship, National academy, Health, Life, Syndrome, Developmental Biology (journal), Princeton University, Society, Gene, University, Cancer, Perelman, Pregnancy, Development, Disease, BPA, Child, Doctor of Philosophy, Therapy, Cell, Genomic imprinting, Nobel Prize, Beckwith–Wiedemann syndrome

ARLINGTON, Va., Jan. 18, 2024 /PRNewswire/ -- March of Dimes, the leading organization fighting for the health of moms and babies, is pleased to announce Marisa Bartolomei, PhD, as the recipient of the 2024 March of Dimes Richard B. Johnston, Jr., MD Prize. This annual award honors an outstanding scientist who has advanced the science that underlies our understanding of pregnancy, birth, and prenatal development. Dr. Bartolomei is a Co-Director of the Epigenetics Institute at the University of Pennsylvania's Perelman School of Medicine, where she is also the Perelman Professor of Cell and Developmental Biology.

Key Points: 
  • This annual award honors an outstanding scientist who has advanced the science that underlies our understanding of pregnancy, birth, and prenatal development.
  • Over her 30-year career, Dr. Bartolomei has made instrumental discoveries on the function and expression of certain genes, called imprinted genes.
  • It is part of March of Dimes' research strategy to address the multi-faceted nature of the maternal and child health crisis.
  • March of Dimes will present the award to Dr. Bartolomei at the 2024 Annual Meeting of the Society for Reproductive Investigation in Vancouver, British Columbia on March 16, 2024.

REMADE Announces Registration Is Open for 2024 REMADE Circular Economy Tech Summit & Conference

Retrieved on: 
Thursday, January 18, 2024
Advanced Materials, MacArthur Foundation, DOE, Renewable energy, Ellen, Partnership, Ellen MacArthur, National academy, John Macarthur (wool pioneer), Aluminium, Systems analysis, Plastic, Environment, EERE, Recycling, Textile, Carbon, Climate change, Conference, Polymer, Energy efficiency, REMADE, Steel, Biodiversity loss, Nature, Public sector, Circular economy, Metal

ROCHESTER, N.Y., Jan. 18, 2024 /PRNewswire/ -- The REMADE Institute, a 168-member public-private partnership established in collaboration with the United States Department of Energy (DOE), is pleased to announce that registration is open for the 2024 REMADE Circular Economy Technology Summit & Conference and conference proceedings from the Institute's inaugural 2023 conference are now available.

Key Points: 
  • ROCHESTER, N.Y., Jan. 18, 2024 /PRNewswire/ -- The REMADE Institute, a 168-member public-private partnership established in collaboration with the United States Department of Energy (DOE), is pleased to announce that registration is open for the 2024 REMADE Circular Economy Technology Summit & Conference and conference proceedings from the Institute's inaugural 2023 conference are now available.
  • "REMADE and our partners are very excited to convene, once again, an in-depth, multidisciplinary, action-based scientific conference and international thought-leadership event addressing all aspects of the circular economy," said REMADE CEO Nabil Nasr.
  • The REMADE Circular Economy Tech Summit & Conference, now an annual event, advances the conversation on a circular approach and how it can benefit nations in meeting their multiple energy, environmental, manufacturing, industrial decarbonization, and economic goals.
  • The 2024 REMADE Circular Economy Technology Summit & Conference is open to REMADE members, non-members, and university students from across the U.S. and around the world.

Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board

Retrieved on: 
Wednesday, January 10, 2024
Stanford University, Leukemia, Monroe Dunaway Anderson, Research, Metastasis, Ipilimumab, Cancer, Autoimmune disease, CODEX, GBM, University, National academy, Bladder cancer, MD Anderson Cancer Center, RNA, Teal, CD28, Defense, EZH2, Nobel Prize, Invention, Translational research, Health, Cell biology, Pathology, Woman, Immunotherapy, SAB, Emil Frei, Patient, Associate, MD, Roche, Burroughs Wellcome Fund, Society, FDA, ATAC, ASCI, Doctor of Philosophy, Clinical trial, Immune system, Pharmaceutical industry

Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.

Key Points: 
  • Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.
  • He co-founded Akoya Biosciences in 2015 and is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine.
  • Dr. Allison has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy.
  • This finding and a great deal of persistence paved the way for the field of immune checkpoint blockade therapy for cancer.

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

Retrieved on: 
Wednesday, January 10, 2024
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, Constellation, Patient, Therapy, Biology, Remyelination, Drug design, ALS, Broad Institute, Multiple sclerosis, Partnership, Harvard Medical School, National academy, GPR17, Venture, Neuroinflammation, MIT, Sympathetic nervous system, Drug development, TYK2, Traffic barrier, Harvard University, Capital, Limited partnership, CNS, Pharmaceutical industry

Myrobalan has the potential to overcome such obstacles with the development of highly selective, brain-penetrant, orally available compounds against promising novel targets involved in demyelination and neuroinflammation.

Key Points: 
  • Myrobalan has the potential to overcome such obstacles with the development of highly selective, brain-penetrant, orally available compounds against promising novel targets involved in demyelination and neuroinflammation.
  • These currently untreatable disease mechanisms have been linked to multiple sclerosis (MS), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and several rare neurological conditions.
  • “Our deep understanding of remyelination and neuroinflammation has broad application in high-unmet need CNS diseases,” said Dr. Jing Wang, CEO & Co-Founder, Myrobalan Therapeutics.
  • Myrobalan Therapeutics' unique strategy holds great promise in overcoming challenges associated with central nervous system diseases.